Get the Stockscreener App
36.77
0.14%
-0.05
After Hours:
36.77
Smith Nephew Plc Adr stock is traded at $36.77, with a volume of 511.16K.
It is down -0.14% in the last 24 hours and up +1.24% over the past month.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
See More
Previous Close:
$36.82
Open:
$36.62
24h Volume:
511.16K
Relative Volume:
0.70
Market Cap:
$15.61B
Revenue:
$5.81B
Net Income/Loss:
$412.00M
P/E Ratio:
39.12
EPS:
0.94
Net Cash Flow:
-
1W Performance:
+0.25%
1M Performance:
+1.24%
6M Performance:
+28.48%
1Y Performance:
+45.68%
1-Day Range:
$36.49
$36.85
1-Week Range:
$35.73
$36.94
52-Week Range:
$23.69
$38.79
Smith Nephew Plc Adr Stock (SNN) Company Profile
Compare SNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNN
Smith Nephew Plc Adr
|
36.77 | 15.61B | 5.81B | 412.00M | 0 | 0.94 |
|
ABT
Abbott Laboratories
|
123.84 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.59 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
358.16 | 136.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.20 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.07 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Smith Nephew Plc Adr Stock (SNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Mar-12-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-24 | Downgrade | Berenberg | Buy → Hold |
| Nov-01-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-24 | Initiated | Deutsche Bank | Buy |
| Jun-05-24 | Upgrade | UBS | Neutral → Buy |
| Nov-28-23 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-03-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-31-23 | Upgrade | HSBC Securities | Hold → Buy |
| Oct-13-23 | Initiated | Stifel | Hold |
| Aug-08-23 | Upgrade | UBS | Sell → Neutral |
| Apr-27-23 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-12-22 | Initiated | Citigroup | Buy |
| Nov-28-22 | Downgrade | UBS | Neutral → Sell |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-28-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-15-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-22 | Upgrade | Redburn | Sell → Neutral |
| Jun-09-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-18-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-01-20 | Initiated | Barclays | Overweight |
| Jul-29-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-21-19 | Initiated | Citigroup | Buy |
| Nov-12-19 | Initiated | Bernstein | Outperform |
| Jul-23-19 | Upgrade | Berenberg | Hold → Buy |
| Feb-08-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Jan-02-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-10-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-01-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-25-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-11-17 | Initiated | Canaccord Genuity | Buy |
| Feb-27-17 | Downgrade | Goldman | Buy → Neutral |
| Jan-19-17 | Initiated | HSBC Securities | Hold |
| Dec-08-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-06-16 | Downgrade | Berenberg | Buy → Hold |
| Feb-26-16 | Initiated | Cantor Fitzgerald | Hold |
View All
Smith Nephew Plc Adr Stock (SNN) Latest News
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT - Sahm
Joint Reconstruction Devices Market 2025-2032: New Technologies are Transforming the Landscape, Reaching $149 Billion by 2032 - GlobeNewswire Inc.
Predictions - sharewise.com
UFC® and Smith+Nephew announce multi-year extension of partnership - The Globe and Mail
Sequoia Financial Advisors LLC Has $357,000 Stock Holdings in Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew schedules third quarter trading report release for November 6 - Investing.com
BlackRock Adjusts Voting Rights in Smith & Nephew - The Globe and Mail
Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant - Sahm
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention - Sahm
Smith & Nephew’s ratings affirmed by Moody’s with positive outlook - Investing.com
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty - The Globe and Mail
Park Avenue Securities LLC Acquires 583 Shares of Smith & Nephew SNATS, Inc. $SNN - Defense World
Smith & Nephew CFO John Rogers relocates to US, receives revised compensation - Investing.com
Citi Keeps Their Hold Rating on Koninklijke Philips N.V. (0LNG) - The Globe and Mail
Smith & Nephew (LON:SN) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Smith & Nephew expands its advanced bioactives portfolio - MarketScreener
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant - Ariva
Smith & Nephew Aligns Director Compensation with Shareholder Interests - The Globe and Mail
Smith & Nephew (LON:SN) Insider Simon Lowth Purchases 355 Shares - Defense World
Smith & Nephew (LON:SN) Insider Katarzyna Mazur Hofsaess Purchases 541 Shares of Stock - Defense World
Scharf ETF Holdings - Quiver Quantitative
FMI Global Equity Q2 2025 Review - Seeking Alpha
FMI All Cap Equity Q2 2025 Review - Seeking Alpha
FMI Large Cap Equity Q2 2025 Review (Mutual Fund:FMIHX) - Seeking Alpha
Smith & Nephew director David King buys USD100,000 in shares - MarketScreener
Smith & Nephew stock hits 52-week high at 36.56 USD - Investing.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for Smith & Nephew (LON:SN) Stock - Defense World
Smith & Nephew Earnings: The Turnaround Started Three Years Ago and Now Bears Fruit - Morningstar
Smith & Nephew's Turnaround Pushes Profitability Higher - Morningstar
Smith & Nephew plc ADR: Rising 11.43% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Smith & Nephew SNATS, Inc. (SNN) Stock Forecasts - Yahoo Finance
What Are Expectations For Smith & Nephew plc ADR (NYSE: SNN) In The Short Term? - stocksregister.com
Upwork Inc (NASDAQ: UPWK) Is Down -0.17% – Is It A Buying Opportunity? - stocksregister.com
FTSE 100 today: Index inches higher; BP beats, Smith & Nephew rallies - Investing.com
Smith & Nephew schedules release of second quarter and half-year 2025 results - Investing.com
Haleon PLC Sponsored ADR (NYSE:HLN) Shares Sold by Bank of New York Mellon Corp - Defense World
Validea's Top Health Care Stocks Based on Martin Zweig - AInvest
SNN’s 2023 Market Dance: Up 12.53% – Time to Invest? - investchronicle.com
Bessemer Group Inc. Purchases 1,701 Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) - Defense World
Smith & Nephew’s Role in the FTSE 100 Healthcare Segment - Kalkine Media
Smith & Nephew (LON:SN) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Smith & Nephew appoints new Non-Executive Director - Investing.com
حصلت شركة سميث+نيفيو على عقد لتوفير أنظمة علاج الجروح بالضغط السلبي لوزارة الدفاع الأمريكية - Sahm
Smith & Nephew plc: Institutional Strength and Dividend Discipline Fuel Undervalued Gem - AInvest
Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹ - The Globe and Mail
Shell Plc Declares Q1 2025 Dividend - DirectorsTalk Interviews
Smith+Nephew reports solid Q1 2025 growth - Investing.com
Smith+Nephew schedules Q1 2025 trading report release - Investing.com
UBS cuts Smith & Nephew stock rating to Neutral, sets GBP1.25 target - Investing.com
Smith & Nephew CEO Deepak Nath's 2024 Total Pay At $7.8 Mln, Annual Report Says - MarketScreener
Smith Nephew Plc Adr Stock (SNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):